Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
ConclusionsThe efficacy of adding bavituximab to sorafenib for the treatment of advanced HCC was inconclusive; however, the combination regimen did not exacerbate toxicities associated with single-agent sorafenib.ClinicalTrials.gov identifierNCT01264705.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Anorexia | Cancer & Oncology | Carcinoma | Clinical Trials | Eating Disorders & Weight Management | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | History of Medicine | Liver Cancer | Oral Cancer | Study | Toxicology